FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a method for in vivo assessment of therapeutic efficiency of a remedy for use in the treatment of complement-related nephropathy. The method provides for administration of a remedy to a rodent, in the genome of which there is a substitution by endogenous locus C3 of a rodent of a rodent gene sequence containing C3 gene exon with a nucleic acid sequence containing at least one human C3 gene exon to form a modified C3 gene. A method is also disclosed for identification of a remedy that suppresses a symptom of complement-related nephropathy in a rodent, in the genome of which there is a substitution by endogenous locus C3 of a rodent of a rodent gene sequence encoding C3 gene exon with a nucleic acid sequence containing at least one human C3 gene exon to form a modified C3 gene.
EFFECT: invention is effective for screening of candidate therapeutic remedies or compounds for the treatment of complement-related nephropathies and liver fibrosis.
17 cl, 31 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANIMALS BY C5 AND C3 | 2015 |
|
RU2713327C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2703139C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2788523C2 |
| ANIMALS CONTAINING HUMANIZED DIPEPTIDYL PEPTIDEASE IV (DPP4) | 2015 |
|
RU2648166C1 |
| NON-HUMAN ANIMALS HAVING HUMANIZED Fc-γ-RECEPTORS | 2015 |
|
RU2700484C2 |
| GENETICALLY MODIFIED T CELL RECEPTOR MICE | 2012 |
|
RU2661106C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| NON-HUMAN ANIMALS HAVING HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 | 2016 |
|
RU2745403C2 |
| METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
| ANIMALS OTHER THAN HUMANS HAVING A HUMANISED CLUSTER GENE OF DIFFERENTIATION 47 | 2015 |
|
RU2728412C2 |
